EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance

Florence M Stel iD, Esther M Zijlstra-Willems, Ad C van Nuenen, Brigitte D M Boeser-Nunnink, Teunis B H Geijtenbeek iD, Neeltje A Kootstra iD

International Journal of Molecular Sciences · 01.08.2026 · 27 (15) · 6883

DOI: 10.3390/ijms27156883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.08.2026. Verfasst von Florence M Stel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Amsterdam UMC Location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: HIV-1, Capsid, Drug Resistance, Viral, HIV Infections. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Holland, Amsterdam UMC Location University of Amsterdam, Amsterdam UMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiretroviral therapy (ART) has proven effective in suppressing HIV-1 replication, but further development of HIV-1 inhibitors is continually driven by the challenge of drug resistance and viral adaptation. The HIV-1 capsid is a promising target for treatment due to its high sequence conservation as well as its crucial role in the viral life cycle. Recently, we have developed a novel capsid-targeting biologic that prevents HIV-1 replication by efficient degradation of newly synthesized capsid. Here, we have investigated the sensitivity to viral escape as well as the breadth of this biologic against HIV-1 subtypes. The capsid-targeting biologic efficiently blocked replication of different primary HIV-1 isolates, and continuous exposure of these viruses to the biologic resulted in viral breakthrough of two out of ten primary HIV-1 isolates tested. Notably, the breakthrough variants did not have amino acid changes in the nanobody epitope but primarily in the matrix region. The breakthrough variants remained sensitive to the biologic albeit to a lesser extent. In the absence of the biologic, breakthrough variants showed increased replication kinetics when compared to their parental virus, suggesting that adaption to the biologic is likely due to the increased viral production and that the target area of the biologic is too conserved for actual escape. This is further underscored by the broad specificity of the biologic as importantly the biologic blocked infection of different HIV-1 subtypes that occur worldwide (A, B, C, D, CRF01_AE, CRF02_AG). These results demonstrate the broad neutralization potential of anti-capsid biologics with a high barrier to resistance, making capsid-targeting inhibitors important for novel antiretroviral drug strategies worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1CapsidDrug Resistance, ViralHIV InfectionsAnti-HIV AgentsAntibodies, NeutralizingHumansVirus ReplicationHIV Antibodies

Stichwörter der Autor:innen

HIV-1anti-capsid biologicnanobodyviral escape

Substanzen

Anti-HIV AgentsAntibodies, NeutralizingHIV Antibodies

Autor:innen und Institutionen

  • Department of Experimental Immunology, Amsterdam UMC Location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Amsterdam Institute for Immunology and Infectious Diseases, 1105 AZ Amsterdam, The Netherlands.

ORCID-Profile: Florence M Stel, Teunis B H Geijtenbeek, Neeltje A Kootstra

Förderung

  • Health Holland
  • Amsterdam UMC Location University of Amsterdam
  • Amsterdam UMC
  • Health~Holland

Zitieren

APA

Stel, F. M., Zijlstra-Willems, E. M., Nuenen, A. C. V., Boeser-Nunnink, B. D. M., Geijtenbeek, T. B. H., & Kootstra, N. A. (2026). Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance. International Journal of Molecular Sciences, 27(15), 6883. https://doi.org/10.3390/ijms27156883

Vancouver

Stel FM, Zijlstra-Willems EM, Nuenen ACV, Boeser-Nunnink BDM, Geijtenbeek TBH, Kootstra NA. Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance. International Journal of Molecular Sciences. 2026;27(15):6883. doi:10.3390/ijms27156883

BibTeX
@article{Stel2026,
  author = {Stel, Florence M and Zijlstra-Willems, Esther M and Nuenen, Ad C van and Boeser-Nunnink, Brigitte D M and Geijtenbeek, Teunis B H and Kootstra, Neeltje A},
  title = {Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6883},
  doi = {10.3390/ijms27156883}
}
Kostenlos starten →